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Summary The mini-BEAM regimen (BCNU, etoposide, cytarabine, melphalan) and its modification 'Dexa-
BEAM' are effective salvage protocols for relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Since
many patients with relapsed lymphoma are eligible for high-dose chemotherapy with autologous stem cell
rescue, we were interested in the suitability of these second line regimens for mobilising peripheral blood
progenitor cells (PBPC). The kinetics of PBPC were studied in 15 patients treated with Dexa-BEAM and
granulocyte colony-stimulating factor (G-CSF). Leukocytes started to rise from <0.5 nL 'on day 18 (16-22)
after Dexa-BEAM, and exceeded 10 nL-' on day 20 (18-28). Peripheral blood CFU-GM peaked on day 21
(19-28) and declined slowly thereafter; the median leukocyte count was 18.7 nL-' (12.2-60) on the day of
CFU-GM-peak. The maximum number of CFU-GM circulating in peripheral blood was inversely correlated
to the duration of leukopenia after Dexa-BEAM. Measurement of CD34 + cells with the monoclonal
antibody 8G12-PE (HPCA-2) predicted the number of CFU-GM precisely in both peripheral blood and
leukapheresis products (r = 0.90-0.95). Two to six leukapheresis procedures yielded 6.39 x 108 mononuclear
cells kg-' (1.82-13.49) containing 44.4 x 104 CFU-GM kg-' (2.2-213.8). Immunophenotypical analysis
revealed that the percentage of CD19 + B cells was ver, low in all collection products (less than 1%). Nine
patients were autografted with PBPC (15.4-213.8 x 10 CFU-GM kg-1) after myeloablative chemotherapy
and experienced rapid and sustained engraftment (Platelets >50 nL- on day + 13 [9-22]).
We conclude that PBPC can be mobilised effectively by Dexa-BEAM plus G-CSF. An adequate timing of
PBPC collection (when the leukocyte count has exceeded 10 nL- 1) and evaluation of the progenitor content of
the leukapheresis products with 8G12-PE will allow to minimise the number of leukaphereses.
High-dose chemotherapy with autologous cell stem rescue is
increasingly being used for treatment of relapsed Hodgkin's
disease (HD) or non-Hodgkin's lymphoma (NHL). Both
autologous bone marrow (BM) and peripheral blood pro-
genitor cells (PBPC) have successfully been employed for
restoring haematopoiesis after myeloblative cytotoxic therapy
(Philip et al., 1987; Kessinger et al., 1989; Brandwein et al.,
1991; Hardingham et al., 1993; Schmitz et al., 1993). Besides
the possibility of less contamination by tumour cells, the
major advantage of autologous PBPC transplantation (PBP-
CT) over autologous BM transplantation (ABMT) appears
to be a more rapid reconstitution of marrow function (Sher-
idan et al., 1992; To et al., 1992). Since the frequency of
PBPC is low in steady-state haematopoiesis (Richman et al.,
1976; DeLuca et al., 1992), mobilisation of progenitor cells
into the blood is mandatory before harvesting via leuka-
pheresis becomes practical. Originally, this was achieved by
administration of myelosuppressive drugs (cytotoxic mobilis-
ation), resulting in considerably increased PBPC levels during
the recovery phase (Richman et al., 1976). Although high-
dose cyclophosphamide has been preferentially used for
mobilising PBPC (To et al., 1989; Gianni et al., 1989; Bender
et al., 1992), other cytotoxic drugs also are effective (Emm-
inger et al., 1990; Siena et al., 1991; Teshima et al., 1992). As
recombinant human haematopoietic growth factors have
become available for clinical application, it has been demon-
strated that the PBPC pool can effectively be expanded by
granulocyte colony-stimulating factor (G-CSF) and granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) (Dii-
hrsen et al., 1988; Socinski et al., 1988; DeLuca et al., 1992).
Combination with cytotoxic therapy may further improve the
yield of CSF-induced PBPC mobilisation (Socinski et al.,
1988; Gianni et al., 1989).
Most patients with relapsed or refractory lymphoma sche-
duled for an autologous stem cell transplant receive salvage
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chemotherapy in order to debulk tumour and test its sen-
sitivity to cytotoxic therapy. Regimens containing carmustine
(BCNU), etoposide, cytarabine, and melphalan, such as the
'mini-BEAM' and the 'Dexa-BEAM' protocols, have shown
quick responses in a substantial number of patients and are
thus widely used in this situation (Stewart et al., 1991;
Chopra et al., 1992; Pfreundschuh et al., 1993). In order to
develop an efficient and economical method for PBPC
harvesting in patients with lymphoma, we were interested in
the suitability of these salvage regimens for mobilising PBPC.
To this end, the kinetics of PBPC were studied in 15 patients
who were treated with Dexa-BEAM and G-CSF to determine
the optimum timing of PBPC collection.
Patients and methods
Patients
From March 1992 to January 1993, 15 consecutive patients
underwent PBPC harvest after Dexa-BEAM for treatment of
relapsed or refractory HD (n = 10) or NHL (n = 5). The
median age was 37 years (range 24-49). Usually, the first
Dexa-BEAM cycle was used for progenitor collection. Most
patients were intensively pretreated, having failed 1-4 chem-
otherapy regimens with or without radiotherapy. Details are
given in Table I.
Treatment regimens
Fully informed consent was obtained before therapy. All
patients received G-CSF (5 ,Lgkg-' s.c.) from day 8 (d8) of
the Dexa-BEAM protocol until the last day of PBPC collec-
tion. The Dexa-BEAM regimen included dexamethasone
3 x 8mg dl-10, BCNU 60mgm 2 d2, etoposide 150-400
mg m-2 d4-7, cytarabine 100mgm-2 ql2h d4-7, and mel-
phalan 20 mg m2 d3. Total white blood count (WBC),
mononuclear cells, CFU-GM, BFU-E, and CD34 + cells
were analysed daily during haematopoietic recovery.
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Table I Patient characteristics
Dexa- Previous
BEAM Previous Previous radio-
UPN Age Sex Disease State cyce no. regimens cycles therapy
P03 24y M HD 2nd relapse 3 3 14 +
P04 36y M HD 2nd relapse 1 3 9 +
P05 26y F HD Refractory 1 1 5
P06 36y F HD 1st relapse 2 3 9 +
P07 45y M HD 3rd relapse 1 3 14 +
P08 47y F NHL 1st relapse 1 1 5 +
P09 25y M HD 2nd relapse 1 4 15 +
P12 48y F HD 1st relapse 1 3 12
P13 42y M NHL Refractory 1 2 3
P14 48y M HD Refractory 1 1 2
P15 37y M NHL 2nd relapse 1 2 13
P17 42y M NHL 1st relapse 2 3 16
P18 49y M NHL 1st CR 1 1 6 -
P19 24y F HD 2nd relapse 1 2 8 +
P20 25y M HD Refractory 1 2 6
Median 37 5F/ I0HD/ 1 2 9 7 + /8-
Range 24-49 lOM 5NHL 1-3 1-4 3-16
For patients proceeding to PBPCT, high-dose chemo-
therapy consisted of cyclophosphamide 6gm-2, etoposide
1000mgm-2 and BCNU 300mgm-2 (CVB) for HD, and
BCNU 300mgm-2, etoposide 800mgm-2, cytarabine (1600
mgm-' and melphalan 140mgm-2 (BEAM) for NHL, re-
spectively (Schmitz et al., 1993). Supportive care was per-
formed as described previously (Schmitz et al., 1988).
Leukapheresis
Leukapheresis was performed with a Fenwal CS3000 blood
component separator (Baxter, Munich, Germany) using a
double-lumen central-venous catheter. Six to 10 ten liters of
blood were processed daily at a flow rate of 30-60 mL
min-'. Each leukapheresis product was cryoconserved in
liquid nitrogen until the day of transplantation at a cell
concentration of 5 x 107mL-1. The patients tolerated the
mobilisation and cell separation procedures well.
Preparation ofcellsfor in vitro analysis
To evaluate the percentage of mononuclear cells (MNC),
Pappenheim-stained smears from each sample of peripheral
blood or the leukapheresis product were used. At least 400
cells per slide were counted. MNC were isolated by density
grade centrifugation over Ficoll/Hypaque (Pharmacia, Frei-
burg, Germany), washed, and adjusted in supplemented
Iscove's modified Dulbecco's medium (IMDM, Life Tech-
nologies, Karlsruhe, Germany).
Progenitor cell assays
CFU-GM were grown by plating 1 x I05 MNC in 0.3% agar
culture medium consisting of 20% FCS and 5% human
placenta-conditioned medium in supplemented IMDM. All
cultures were done in triplicate. After 14 days of incubation
in a humidified atmosphere of 5% CO2 at 37°C, colonies
(>40 cells) were counted. For BFU-E, MNC were plated in
methylcellulose containing 30% FCS, purified human eryth-
ropoietin (Terry Fox Laboratories, Vancouver, Canada) and
PHA-leukocyte-conditioned medium as supplements. The
further procedure was similar to that of CFU-GM; BFU-E
were counted after 14 days. Counting was performed by the
same individual throughout the whole study.
Immunophenotyping
Preparation of MNC for flow cytometry has been described
elsewhere (Dreger et al., 1993b). In brief, cells were sus-
pended with PE- and FITC-conjugated specific monoclonal
antibodies or PE/FITC-conjugated irrelevant isotype-specific
antibodies (DAKO, Hamburg, Germany) in phosphate-
buffered saline containing 0.2% sodium azide. After 30 min
of incubation and fixation with 1% formaldehyde, flow cyto-
metry was performed with a FACScan flow cytometer (Bec-
ton Dickinson, Heidelberg, Germany). The antibodies used
were: 8G12-PE (HPCA-2, CD34), Leu-19-PE (CD56, both
from Becton Dickinson), MT310-PE (CD4), UCHT1-FITC
(CD3), DK25-FITC (CD8), HD37-FITC (CD19, all from
DAKO), and QBENDlO-FITC (CD34, Immunotech, Mar-
seille, France). Absolute numbers of CD34 + cells were cal-
culated from the total percentage of 8G12-PE brightly
stained cells, employing a window that excludes virtually all
background fluorescence (0.02% or less positive cells in the
unspecific control). Absolute numbers of lymphocyte sub-
populations were calculated from the percentage of positive
cells in a lymphocyte gate which contained virtually all
CD3 +, CDl9 + and CD56 + cell using the corresponding
differential blood count.
Statistical analysis
Regression and correlation analyses were performed with
LOTUS software. Spearman's rank correlation test was used
for calculating the correlation between the speed ofleukocyte
recovery and PBPC peaks, and the amount of cellular com-
ponents transplanted and time to engraftment. A P value of
<0.05 was considered as significant.
Results
Kinetics ofhematopoietic recovery and PBPC mobilisation
after Dexa-BEAM
The WBC started to rise from <0.5 nL-' on day 16-22
(median 18) after start of Dexa-BEAM, and exceeded 10.0
nL-' on day 18-28 (median 20). Peripheral blood CFU-GM
peaked on day 19-28 (median 21) and declined slowly
thereafter. In no instance did the CFU-GM peak occur
before the WBC had exceeded 10.0 nL 1; usually, the peak
was reached 1 or 2 days after this event (Figure 1). The
median WBC on the day of CFU-GM peak was 18.7 nL-'
(range 12.2-60). Accordingly, in the last 11 patients PBPC
collection was performed after the WBC had increased to
more than 10.0 nL-' to avoid unnecessary leukapheresis.
CFU-GM maxima also coincided with platelet recovery after
Dexa-BEAM (unsustained platelet count > 50 nL- ), but this
association was less strict than that of CFU-GM and WBC
(Figure 1). For further details see Table I.
The peak CFU-GM mL-' blood (0.2-44.1 x 103) was inver-
sely correlated to the number of days to reach a WBC of952 P. DREGER et al.
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Figure 1 Kinetics of peripheral blood CFU-GM in relation to WBC a, and platelet recovery b, after Dexa-BEAM (n = 11). The
ordinate depicts the medians of the CFU-GM percentages on the corresponding days relative to the individual CFU-GM maxima
(= 100%).
> 10 nL-' (rs = - 0.68, P<0.025) and to the number of
days to reach a WBC of >20 nL-' (rs = - 0.80, P<0.005).
Among the patients for whom PBPC kinetics were available,
three had strikingly low numbers of peripheral blood CFU-
GM (peak CFU-GM <1 x 103 mL-'); in all of them WBC
recovery was slow and incomplete as indicated by the fact
that a WBC of >20 nL-' was not reached in spite of
continued G-CSF application (Table II). All patients with
'normal' CFU-GM values in their peripheral blood achieved
a WBC of > 10 nL-' within 3 weeks from the start of
Dexa-BEAM and exceeded a WBC of 20 nL-' 1 or 2 days
later. A clear-cut relationship between PBPC maxima and the
intensity of pretreatment was not evident.
CD34-positive cells
In the first three patients, labelling of CD34-positive cells was
performed with QBENDIO-FITC. However, as the fluor-
escence intensity obtained with this conjugate was found to
be very low, a reliable discrimination of CD34 + cells was
not possible. Thus, in all subsequent patients, CD34 + cells
were also stained with 8G12-PE. This antibody, which binds
to a chymopapain-resistant epitope on the CD34 molecule
(Lansdorp et al., 1989; Civin et al., 1990), produces a bright
specific fluorescence, allowing the reproducible quantitation
of even very small amounts of peripheral blood CD34 +
MNC (>0.1% of gated cells). In our study, the CD34 +
Table II Kinetics of PBPC mobilisation and WBC recovery after Dexa-BEAM
WBC WBC WBC Platelets CFU max CD34 max
>0.5 nL- > 10nL-' >20 nL-' >50 nL- CFU-max X103mL'1 x 103mL-'
UPN day day day day day blood blood
P03 17 19 20 naa na na na
P04 19 21 23 21 22 7.2 na
P05 na 19 na na na na na
P06 22 28 nrb 27 28 0.52 9.3
P07 20 23 nr 25 24 0.2 3.4
P08 17 20 21 21 21 3.19 49.5
P09 16 18 20 18 19 44.06 296.6
P12 na na na na na na na
P13 19 22 23 21 22 11.25 166.7
P14 18 20 21 na na na na
P15 17 19 19 17 20 31.56 258
P17 17 18 19 19 19 8.59 93
P18 19 21 nr 20 24 0.5 9.1
P19 18 20 21 21 20 4.37 26.3
P20 17 19 21 20 21 8.36 42.8
Median 18 20 21 21 21 7.2 46.2
Range 16-22 18-28 19->28 17-27 19-28 0.2-44.06 3.4-296.6
n 13 14 13 11 11 11 10
aNot available. bNot reached.
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MNC populations demonstrated almost entirely low right-
angle light scatter and low to intermediate forward light
scatter characteristics, corresponding to the 'lymphocyte
window' as defined by SIENA et al. (Siena et al., 1989)
(Figure 2).
When measured with 8G12-PE, the kinetics of peripheral
blood CD34 brightly positive cells paralleled those of CFU-
GM very closely (r = 0.90); the relation might be fitted by a
linear regression line described by the equation y = 0.084 +
0.102x, in which x corresponds to the CD34 + cell count and
y to the CFU-GM count. The slope of the regression line
indicates that CFU-GM were present at 0.102 the number of
CD34 + cells, or, vice versa, CD34 + cells were 9.8 times
more frequent than CFU-GM. Considering each individual
pair of samples, five to 20 CD34 + cells were found per one
CFU-GM. The maximum percentage of CD34 + cells ranged
from 0.16 to 4.21% (median 2.22%) of MNC, according to
absolute numbers of 3.4-296.6 x 103 CD34 + cells per mL
blood. In patient P07, who displayed the lowest numbers of
PBPC, flow cytometry yielded 0.04-0.16% CD34 + cells
without clear correlation to the CFU-GM counts, indicating
a limited precision of CD34 + cell quantitation when very
small percentages of CD34 + cells are present. (This patient
was not included in the analysis depicted in Figure 3).
Linear regression analysis of CFU-GM x 104/CD34 + cells
x 105 in the harvests of 25 leukapheresis procedures again
revealed a strong correlation between these two parameters
(r = 0.95; y = 8.13 + 0.784x, corresponding to 12.8 CD34 +
cells per CFU-GM). The correlation between BFU-E and
CD34 + cells was less striking (r = 0.75; y = 2.55 + 0.255x,
corresponding to 39.2 CD34 + cells per BFU-E; Figure 3).
Composition ofthe leukapheresis products
Overall, 2-6 leukapheresis procedures yielded 1.82-13.49 x
108 MNC kg-' (median 6.39), containing 2.2-213.8 x 104
CFU-GM kg-' (median 44.4), 4.8-101.1 x 104 BFU-E kg-'
(median 26.8), and 0.14-4.52 x 108 lymphocytes (median
1.31, Table III). When performing an immunophenotypical
analysis on the leukapheresis products of 9 patients, we
found 16.2-269.7 x 105 CD34 + cells kg-' (median 57), 28-
345.9 x 106 CD31 + T cells kg-' (median 116), 20.5-
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Figure 2 Flow cytometry of CD34 + cells in the peripheral blood of patients treated with Dexa-BEAM + G-CSF. Shown are
examples of bivariate plots displaying right-angle scatter properties vs staining with 8GI2-PE (right panels) or irrelevant mouse
IgG-PE (left panels). Calculation windows include 0 vs 0.20 (UPN P18), and 0 vs 1.90% PE-postive cells (UPN P20).
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251.2 x 10' CD4 + T cells kg-' (median 59.7), 7.1-100.4 x
106 CD8 + T cells kg-' (median 53.6), and 2.6-98 x 106
CD56 + CD3- NK cells kg-' (median 23.8). The percentage of
CD19 + B cells was remarkably low in all collection prod-
ucts (usually less than 1%), resulting in a B cell content of
0-5.9 x 106 cells kg-' (median 0.7).
Engraftment after PBPC reinfusion
Nine patients have been autografted with PBPC (15.4-
213.8 x 104 CFU-GM kg- ) after myeloablative chemother-
apy ('CVB' or 'BEAM' regimen). All experienced rapid and
sustained engraftment (neutrophils >0.5 nL ' on day 8-14
[median 10], untransfused platelets >20 nL' on day 7-14
[median 10], and platelets >50 nL-' on day 9-22 [median
13]) (Table IV). One patient was given a PBPC graft contain-
ing 4.8 x 104 CFU-GM kg-', and, in addition, autologous
marrow containing 3.5 x 104 CFU-GM kg-'. Although recei-
ving stem cells from both sources, this patient engrafted
relatively slow; in particular, the normalisation of the platelet
count was delayed (platelets > 50 on day + 199). Overall, the
amount of CFU-GM infused showed an inverse correlation
to the number of days needed to achieve an unsupported
platelet count of >20 nL-' (rs = - 0.73, P<0.02) or > 50
nL-' (rs =-0.74, P<0.01, Spearman's rank correlation
test).
Discussion
The data presented here demonstrate that PBPC can be
effectively mobilised by salvage combination chemotherapy
(Dexa-BEAM) plus G-CSF. Although it has been recom-
mended that leukapheresis after cytotoxic mobilisation
should start as soon as WBC have reached 1 nL-' (Gianni et
al., 1989; Siena et al., 1989; Emminger et al., 1990), and this
practice has been adapted for combined cytotoxic/CSF-
mediated mobilisation (Siena et al., 1991; Teshima et al.,
1992), our experience indicates that the optimum time for
harvesting PBPC after Dexa-BEAM + G-CSF is not before
the WBC has increased to more than 10 nL-'. If at this time
leukapheresis is not possible, sufficient amounts of PBPC can
still be collected on at least five subsequent days, provided
the G-CSF administration is continued. The absolute
numbers of PBPC present in the circulation correlated well
with the speed and completeness of WBC recovery, i.e. indi-
viduals who exhibited a leukocyte count of 10 nL-' relatively
late and never reached 20 nL-' displayed CFU-GM maxima
that were 10-100 times lower than those seen in patients
with a rapid WBC recovery to >20 nL-'. This observation
matches findings obtained in cytotoxic mobilisation (Emm-
inger et al., 1990).
As reported for other mobilisation regimens, CFU-GM
maxima were also associated with platelet recovery after
CFU-GM mL-' (xlOE3)
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Figure 3 Correlations between CD34 + cells and a, CFU-GM in 57 peripheral blood samples from 12 patients, b, CFU-GM in 25
leukapheresis products from nine patients, and c, BFU-E in 25 leukaphereis products from nine patients. Calculations were done
using linear regression analysis, for clarity, plots are given on a logarithmic scale.
Table III Composition of the leukapheresis products
No. of CD34 CFU-GM BFU-E MNC Lymphoc.
UPN apha x 105kg-' x 10kg-' xJO4kg-' x 108kg-' x 108kg-'
P03 6 na 4.8 na 13.49 na
P04 4 na 50.5 14.2 4.09 1.51
P05 4 na 15.2 6.2 5.84 0.21
P06 4 na 2.2 4.8 1.82 0.14
P07 4 na 3.5 na 4.99 0.45
P08 4 na 43.3 12.6 8.66 1.41
P09 3 175.7 203.2 33 10.35 1.19
P12 3 57 65.8 29.5 8.17 4.52
P13 3 269.7 206.2 32.7 8.17 1.51
P14 3 24.4 19.4 10.9 7.06 2.4
P15 2 245.8 213.8 101.1 9.81 1.71
P17 2 54.9 44.4 26.8 6.39 1.2
P18 3 16.2 12 9.1 3.74 1.02
P19 3 35.2 65.8 27.9 5.58 0.31
P20 3 62.6 110.3 32.8 5.47 1.79
Median 3 57 44.4 26.8 6.39 1.31
Range 2-6 16.2-269.7 2.2-213.8 4.8-101.1 1.82-13.49 0.14-4.52
n 15 9 15 13 15 14
aNumber of leukaphereses
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Table IV Kinetics of engraftment after PBPC reinfusion
CFU-GM Neutrophils Platelets Platelets
infused >0.5 nL-' >2OnL' >5OnL-' Hosp.
UPN (x 1O4 kg-') (day) (day) (day) (days)
P03 4.8a + 10 + 20 + 199 19
P04 50.5 + 10 + 12 + 18 16
P05 15.2b + 10 + 10 + 14 14
P06 22.6c + 14 + 14 +22 23
P08 43.3b + 13 + 10 + 13 14
P09 203.2 +8 +8 +9 11
P12 65.8b + 11 + 10 + 10 16
P13 206.2 + 9 + 10 + 13 21
P14 19.4 + 10 + 11 + 16 18
P15 213.8 +8 +7 + 11 15
Median 46.9 10 10 13 16
Range 4.8-213.8 8- 14 7-20 9- 199 11 -23
aAutologous BM containing 3.52 x 104 CFU-GM kg-' was administered simultaneously. bNo G-CSF after PBPC infusion. clncluding
20.4 x 104 G-CSF-mobilised CFU-GM kg-' obtained on a separate occasion.
Dexa-BEAM (Teshima et al., 1992; Emminger et al., 1990).
However, with regard to timing of leukapheresis, the leuko-
cyte count appears to be the more suitable indicator of PBPC
expansion because WBC recovery usually becomes evident
2-3 days before the critical value (10 nL-') is reached,
whereas the platelet rise often is obscured by platelet trans-
fusions. Moreover, CFU-GM peaks were always preceded by
achievement of the critical leukocyte value (10 nL-') but not
of the critical platelet value (50 nL-').
While it is well documented that the addition of growth
factors strongly increases the efficacy of cytotoxic PBPC
mobilisation, investigations indicating the augmentation of
CSF-mediated mobilisation by cytotoxic therapy are sparse.
Accordingly, in our protocol the importance of Dexa-BEAM
for expanding the PBPC pool is not clearly defined. How-
ever, the relevance of chemotherapy in this setting is under-
lined by the fact that we were not able to collect 100 x I04
CFU-GM kg-' or more with 2-3 leukapheresis in a limited
number of patients mobilised with G-CSF alone, although
previous treatment in general was less intensive than in the
cohort treated with Dexa-BEAM + G-CSF (unpublished ob-
servations). Larger patient numbers, however, are required to
draw definite conclusions on this topic.
The number of CFU-GM necessary for successful trili-
neage engraftment has been a subject of controversy; recom-
mended minimum CFU-GM doses range from 10 x 104 to
50 x 104 kg-' (Siena et al., 1991; Teshima et al., 1992; To et
al., 1986; To & Juttner, 1987). This discrepancy may reflect
differences in the CFU-GM assays employed, in the agents
used for mobilisation, and in the underlying diseases. In our
series, rapid and complete engraftment was achieved in each
patient who received 10 x 104 CFU-GM kg-' or more; the
single patient transplanted with 4.8 x 104 CFU-GM kg-'
showed delayed platelet recovery in spite of simultaneous
administration of autologous bone marrow. Thus, fewer than
10 X 104 CFU-GM kg-' (or 20 x 105 CD34+ cells kg-')
would appear insufficient to ensure complete engraftment in
this setting. Altogether, engraftment after transplantation of
Dexa-BEAM + G-CSF-mobilised PBPC compares favourably
with the recovery of 29 historical control patients with lym-
phoma grafted with autologous bone marrow (platelets > 20
nL-' on day 16-143 [median 25], platelets >50 nL-' on day
20-235 [median 31], manuscript in preparation).
The relationship between CD34 and CFU-GM in peri-
pheral blood is well-acknowledged (Bender et al., 1992; Siena
et al., 1989; Siena et al., 1991; Brugger et al., 1992; Mat-
sunaga et al., 1993). However, the correlation found in the
present series is much stronger than in most previous studies,
which reported correlations between CD34 and CFU-GM
mL-' ranging from r = 0 to r = 0.89 (Bender et al., 1992;
Siena et al., 1989; Siena et al., 1991; Brugger et al., 1992;
Matsunaga et al., 1993; Janssen et al., 1992; Haas et al.,
1992). This may have various reasons: (1) As we and others
have observed (Lansdorp et al., 1989), the affinity and the
degree of unspecific binding between different CD34 MoAbs
and conjugates varies considerably. A less discriminating
CD34 conjugate or indirect CD34 labelling may include
unspecific fluorescence and thus affect the CD34/CFU-GM
correlation (Brugger et al., 1992; Janssen et al., 1992; Haas et
al., 1992). On the contrary, 8G12-PE produces an intensive
staining of CD34 + cells with low right-angle light scatter
and low to intermediate forward light scatter characteristics,
allowing a narrow gating on bright fluorescent cells that
excludes unspecific fluorescence and dim CD34 + cells. Using
this technique, a clear-cut identification and reproducible
quantification of even small proportions of CD34 + cells is
possible. Probably due to the exclusion of cells of uncertain
specificity and dim CD34 + cells, the relative and absolute
numbers of CD34 + cells were lower on a per mL and per
CFU-GM basis in this study than in others in which an
indirect CD34-labelling was employed (Siena et al., 1989;
Matsunaga et al., 1993), but similar to the results obtained
by SIENA et al. who used a 8G12-FITC conjugate (Siena et
al., 1991). (2) The fact that colony counting was performed
by the same person throughout the whole study may have
contributed to the strong CD34 + cell/CFU-GM correlation
observed. (3) Finally, the degree of correlation between
CFU-GM and CD34 + cells may depend on the method of
PBPC mobilisation (Brugger et al., 1992; Janssen et al.,
1992). Altogether, in our study, the CD34 + cell/CFU-GM
ratios ranged consistently between 20:1 and 5:1, implying
that a leukapheresis yield of >20 x I05 CD34 + cells kg-'
reliably predicted for a CFU-GM content of > 10 x 104
kg-'.
When analysing the cellular components of the collection
products by immunophenotyping, we found that CD19 + B
cells were strongly reduced or undetectable in the PBPC
grafts. This phenomenon was much more pronounced in the
present series than observed after cytotoxic mobilisation with
other agents (Kiesel et al., 1989), and paralleled findings
obtained after BM transplantation (BMT), where B cells
have been reported to be virtually absent from the peripheral
blood in the first few weeks after transplant (Ault et al.,
1985; Aotsuka et al., 1991; Dreger et al., 1993b). Thus,
Dexa-BEAM appears to produce some kind of 'in vivo B cell
depletion' of PBPC grafts. Since PBPCT is used in patients
with B cell NHL with BM involvement (Kessinger et al.,
1989; Hardingham et al., 1993), this finding is of particular
importance because Dexa-BEAM plus G-CSF might be em-
ployed to 'purge' autologous stem cell grafts of such patients.
The NK cell/T cell ratios in the PBPC grafts were in the
range expected for normal blood and different from those
seen early after BMT, where the NK cell compartment is
increased (Ault et al., 1985; Aotsuka et al., 1991). The PBPC
grafts contained a median T cell dose of 1.16 x 10 kg-', or
at least three times more T cells than an average BM graft
(Mitsuyasu et al., 1986). Given that T cells play a role in
engraftment of allogeneic and autologous BM (Martin,956 P. DREGER et al.
1990), the high T cell dose contaminating PBPC grafts may
contribute to the fast hematopoietic recovery after PBPCT.
On the other hand, the high T cell content of PBPC grafts
might be a major obstacle for the use of G-CSF-mobilised
PBPC in the allogeneic setting (Dreger et al., 1993a), where T
cells are thought to represent the main carriers of graft-
versus-host reactivity.
Taken together, Dexa-BEAM plus G-CSF can mobilise
large amounts of PBPC that are capable of mediating rapid
and sustained haematopoietic recovery after high-dose chem-
otherapy. The progenitor cell content of the leukapheresis
produce correlates with the speed of leukocyte recovery after
Dexa-BEAM and can rapidly and reliably be assayed by
measurement of 8G12-PE (CD34) brightly positive cells.
From a practical point of view, PBPC collection should start
immediately after the WBC has exceeded 10.0 nL1 and
might be terminated as soon as more than 20 x 105 CD34 +
cells are harvested. This schedule (which should apply also to
patients treated with the very similar mini-BEAM protocol)
will allow asservation of autologous stem cells with a mini-
mum number of leukaphereses, minimum costs, and without
causing delay in continuation of salvage chemotherapy.
We thank the staff of the dialysis, haematology and bone marrow
transplantation wards for excellent patient care and cooperation. The
technical assistance of Ms Susanne Holst and Ina Wertz is gratefully
acknowledged.
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